Roche dips a toe in the lucrative anti-obesity market
05/12/23 -"With the >$3bn Carmot Therapeutics acquisition, Roche has entered the race in the burgeoning anti-obesity market. While, against the backdrop of patent expiries and R&D setbacks, Roche’s share ..."
Pages
73
Language
English
Published on
05/12/23
You may also be interested by these reports :
01/06/25
CureVac has repositioned itself as an early-stage biotech company following the out-licensing of its infectious disease portfolio to GSK. The deal ...
30/05/25
Faes Farma (+25% ytd) has been one of the best performing European pharmas in our coverage this year, driven by the strength of its operations and ...
30/05/25
After some of the key patent expiries at the start of this decade, Lundbeck has been growing at a healthy pace, on the back of its four main ...
28/05/25
While we have moderated our 2025-26 earnings estimates, we have increased our out-year growth assumptions for sales and EBITDA to 3% (vs. 2% ...